Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Autonomix Medical, Inc. Common Stock(AMIX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for AMIX
09/25/2026: AMIX (1-star) is currently NOT-A-BUY. Pass it for now.
Autonomix Medical is a clinical-stage medical device company focused on developing a minimally invasive, catheter-based technology for treating nervous system disorders. Its primary strength lies in its specialized R&D efforts to address nerve-related pain through advanced ablation. The main investment story centers on the potential for its proprietary platform to successfully navigate clinical trials and achieve regulatory approval. However, the company faces significant risks, including the absence of current revenue, heavy reliance on ongoing funding, and intense competition from major medical device players. This stock is suitable for speculative investors who understand the high-risk, high-reward nature of early-stage medical device development.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high-risk, high-reward potential based on clinical-stage technology development. |
| Momentum investor | Weak fit | The stock is highly speculative and subject to clinical trial news cycles rather than consistent momentum trends. |
| Value investor | Weak fit | There is no current earnings or revenue base to justify a traditional value-based valuation. |
| Dividend investor | Weak fit | The company is not cash-flow positive and does not pay a dividend. |
| Low-risk investor | Weak fit | The high volatility and clinical failure risk make this unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage stocks are highly sensitive to trial outcomes and funding news. |
| Valuation risk | High | Valuations for pre-revenue companies are highly speculative and prone to rapid adjustments. |
| Competition risk (Large medical device firms) | High | Competitors like Medtronic have massive R&D budgets and established market access. |
| Business quality | Medium | The business relies entirely on the successful validation of its single, early-stage platform. |
| Dividend income | Low / none | This is a non-dividend paying growth stock. |
| Execution risk | High | The company must successfully navigate complex clinical and regulatory hurdles to exist commercially. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 7.88M USD | Price to earnings Ratio - | 1Y Target Price 58.8 |
Price to earnings Ratio - | 1Y Target Price 58.8 | ||
Volume (30-day avg) 1.6M shares | Beta -0.99 | 52 Weeks Range 2.44 - 32.55 | Updated Date 09/26/2026 |
52 Weeks Range 2.44 - 32.55 | Updated Date 09/26/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -31.05 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Development | Research, design, and testing of the Autonomix catheter system. | The company does not currently generate revenue; investors are betting on the future potential of their medical technology. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -2.89M | Price to Sales(TTM) - |
Enterprise Value -2.89M | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 1.96M | Shares Floating 886.89K |
Shares Outstanding 1.96M | Shares Floating 886.89K | ||
Percent Insiders 5.73 | Percent Institutions 2.88 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Autonomix Medical, Inc. Common Stock
Exchange NASDAQ | Headquarters The Woodlands, TX, United States | ||
IPO Launch date 2024-01-29 | CEO - | ||
Sector Healthcare | Industry Medical Devices | Full time employees 8 | Website https://autonomix.com |
Full time employees 8 | Website https://autonomix.com | ||
Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders of nervous system. The company's technology platform includes a catheter-based system incorporating microchip-enabled sensing architecture designed to detect low-amplitude neural signals from within the vascular system. It develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders. Autonomix Medical, Inc. was incorporated in 2014 and is headquartered in The Woodlands, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.